Evidence map›Paper›PMID 41334931›Full record

ArticleThe Journal of infectious diseases2026

Chlamydia trachomatis-specific T Cell Immunity Reflects Widespread Exposure in South African Adolescents and Young Women.

Rubina Bunjun, Micaela Lurie, Smritee Dabee, Shaun Barnabas, Venessa Maseko, Shameem Z Jaumdally, Hoyam Gamieldien, David A Lewis, Heather B Jaspan, Katherine Gill and 2 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rubina BunjunInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-8471-163X
Micaela LurieInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-6993-0420
Smritee DabeeInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-8373-9593
Shaun BarnabasInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-4819-9501
Venessa MasekoNational Health Laboratory Service, Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0002-9707-9485
Shameem Z JaumdallyInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Hoyam GamieldienInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
David A LewisDivision of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Heather B JaspanInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Katherine GillDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Linda-Gail BekkerInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0755-4386
Jo-Ann S PassmoreInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0009-0002-3151-3514

Funding

Desmond Tutu Health FoundationEuropean and Developing Countries Clinical Trials SP-2011-41304-038European UnionFogarty FoundationFondation Botnar TMA2020CDF-3187HIV Vaccine Trials NetworkNational Research FoundationPoliomyelitis Research FoundationSouth African Medical Research Council
6 · The paper itself

Abstract

backgroundChlamydia trachomatis remains the most prevalent bacterial sexually transmitted infection worldwide, disproportionately affecting adolescent girls and young women (AGYW). Vaccine development is hindered by a limited understanding of protective immunity, particularly in the context of multiple exposures and immunopathology.

methodsWe characterized mucosal inflammation and systemic immune responses to C. trachomatis in South African AGYW (n = 145), stratified by exposure history based on nucleic acid amplification testing (NAAT) and serology (Ab). Specifically, cervicovaginal cytokines, cervical T cell activation, and C. trachomatis-specific CD4+ T cell responses were assessed.

resultsA NAAT+/Ab + status, signifying untreated/recurrent infection, was associated with increased cervical T cell activation. These women all had detectable C. trachomatis-specific CD4+ T cells in blood; however, the magnitude of the response was 2.4-fold lower than in NAAT-/Ab + (cleared infection) or NAAT+/Ab- (primary infection) groups. C. trachomatis-specific multifunctional CD4+ T cells were highest in NAAT-/Ab + women, and nearly absent in those who were NAAT+/Ab +. Notably, systemic C. trachomatis-specific Th1 responses were overall inversely correlated with genital tract concentrations of inflammatory cytokines, including IL-1β, TNF, and IL-17A.

conclusionsBoth the magnitude and quality of the systemic CD4+ T cell responses are critical components of protective immunity to C. trachomatis and may limit mucosal immunopathology, informing vaccine strategies in high-risk populations.

Indexed as

CD4-Positive T-LymphocytesChlamydia InfectionsChlamydia trachomatisAdolescentAdultCervix UteriCytokinesFemaleHumansSouth AfricaVaginaYoung AdultCytokinesChlamydia trachomatiscytokinesgenital tractserologyT cells

Identifiers

PMID41334931
PMCPMC13017485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.